JCPOA

Trump Explodes at CIA over Iran: “Naive and Passive,” “Go Back to School!”

Ann Arbor (Informed Comment) – Our great leader has delivered himself of some weighty pronouncements about Iran, about which he knows not a single little thing, likely even where exactly it is. He called the US intelligence agencies “passive and naive” on Iran, said that Tehran had become less active since Trump violated the 2015 nuclear deal, said Iran’s economy is crashing, and urged Director of National Intelligence Dan Coats and CIA director Gina Haspel to “go back to school.”

France, Germany, UK Launch a New ‘Non-Dollar’ Mechanism to Trade with Iran, But Will it Work?


Patrick Henningsen

21st Century Wire
Money talks, and no one knows this better than the current occupant of 1600 Pennsylvania Avenue. It’s how the Trump Administration communicates with its enemies, as well as with its allies – through the application powerful long-range financial instruments. But Europe is moving in for another attempt at breaking Washington’s blockade of Iran.

EU Launches INSTEX To Facilitate Trade, Bypass US Sanctions on Iran

In a move sure to unleash fury from the Trump administration, the European Union has announced it has set up a transactions channel with Iran to bypass U.S. sanctions. The launch of INSTEX — or “Instrument in Support of Trade Exchanges” — by France, Germany, and the UK will allow non-dollar trade with Iran and is being described as facilitating humanitarian goods-related transactions only, including food, medicine, and medical equipment.

US Sanctions on Iran Depriving Country’s Cancer Patients of Essential Treatment

TEHRAN, IRAN – The recent imposition of crippling sanctions against Iran by the United States government has made life increasingly difficult for everyday Iranians, as essential supplies are becoming more difficult to come by with each passing day. However, certain vulnerable groups, such as Iran’s cancer patients, are bearing the brunt of the burden caused by the sanctions, as the cost of the average cancer treatment has now doubled and the supply of crucial medication has dwindled to new, troubling lows.